Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation
Download
index.pdf
Date
2024-01-01
Author
Temizoz, Burcu
Shibahara, Takayuki
Hioki, Kou
Hayashi, Tomoya
Kobiyama, Kouji
Lee, Michelle Sue Jann
Surucu, Naz
Sag, Erdal
Kumanogoh, Atsushi
Yamamoto, Masahiro
Gürsel, Mayda
Ozen, Seza
Kuroda, Etsushi
Coban, Cevayir
Ishii, Ken J.
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
7
views
4
downloads
Cite This
5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a mouse-selective stimulator of interferon gene (STING) agonist exerting STING-dependent anti-tumor activity. Although DMXAA cannot fully activate human STING, DMXAA reached phase III in lung cancer clinical trials. How DMXAA is effective against human lung cancer is completely unknown. Here, we show that DMXAA is a partial STING agonist interfering with agonistic STING activation, which may explain its partial anti-tumor effect observed in humans, as STING was reported to be pro-tumorigenic for lung cancer cells with low antigenicity. Furthermore, we developed a DMXAA derivative—3-hydroxy-5-(4-hydroxybenzyl)-4-methyl-9H-xanthen-9-one (HHMX)—that can potently antagonize STING-mediated immune responses both in humans and mice. Notably, HHMX suppressed aberrant responses induced by STING gain-of-function mutations causing STING-associated vasculopathy with onset in infancy (SAVI) in in vitro experiments. Furthermore, HHMX treatment suppressed aberrant STING pathway activity in peripheral blood mononuclear cells from SAVI patients. Lastly, HHMX showed a potent therapeutic effect in SAVI mouse model by mitigating disease progression. Thus, HHMX offers therapeutic potential for STING-associated autoinflammatory diseases.
Subject Keywords
DMXAA derivative
,
HHMX
,
partial agonist
,
SAVI
,
STING
URI
https://hdl.handle.net/11511/109394
Journal
Frontiers in Immunology
DOI
https://doi.org/10.3389/fimmu.2024.1353336
Collections
Graduate School of Natural and Applied Sciences, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
B. Temizoz et al., “5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation,”
Frontiers in Immunology
, vol. 15, pp. 0–0, 2024, Accessed: 00, 2024. [Online]. Available: https://hdl.handle.net/11511/109394.